A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma

INTRODUCTION: Nivolumab has been proven to prolong overall survival as a second-line therapy for patients with advanced renal cell carcinoma (RCC) in a phase III clinical trial. However, versatile biomarkers have not been established to predict the efficacy of nivolumab against target disease. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Bando, Yukari, Hinata, Nobuyuki, Omori, Takashi, Fujisawa, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924736/
https://www.ncbi.nlm.nih.gov/pubmed/31826889
http://dx.doi.org/10.1136/bmjopen-2019-030522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924736/
https://www.ncbi.nlm.nih.gov/pubmed/31826889
http://dx.doi.org/10.1136/bmjopen-2019-030522

Ejemplares similares